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Abstract
There are many misconceptions among the general public
regarding the administration of vaccinations during pregnancy. It is imperative for pharmacists to be current regarding guidelines and updates about recommended vaccines.
Data from the Centers for Disease Control and Prevention
(CDC) indicate that while some vaccines are highly recommended during pregnancy, others have limited safety data or
are contraindicated. As new data emerges on the safety and
efficacy of immunizations during pregnancy, pharmacists
should continue to review the literature to stay up-to-date on
vaccination recommendations. The CDC also has information
available for pharmacists and other health care professionals
regarding the use of other vaccines during pregnancy, including vaccines for travel, not covered in this article.
Background
Administering adult immunizations has become an important role of the pharmacist. The availability of the pharmacist
to the public, including weekends and extended hours, places
the pharmacist in a unique position in patient care to have a
major impact on reducing vaccine-preventable illnesses and
deaths.1 Healthy People 2020 indicates the significance of
this topic, as one of its objectives is to "increase immunization rates and reduce preventable infectious diseases." 2 However, despite progress in this endeavor, it is estimated that
approximately 42,000 adults and 300 children in the United
States will die each year from vaccine-preventable diseases. 2
Some speculate that one of the reasons the United States has
fallen short of the national goal is due to misconceptions the
public may have about the safety and efficacy of current
vaccines. These misconceptions may be magnified during
pregnancy, when special concern is taken for the mother and
unborn child. As pharmacists have the opportunity to educate patients about the importance of vaccines, and also may
be able to administer certain vaccines per state laws, it is
imperative for pharmacists to be up-to-date on the current
guidelines about recommended vaccines for pregnant
women.
There are a few general principles regarding pregnancy and
vaccine safety. First, administering live, attenuated viral or
live bacterial vaccines is contraindicated in pregnant women
due to the theoretical risk of transmitting to the developing
fetus.3.4 Second, considerations of risks and benefits to individual patients in the context of general guidelines must be
considered (Table 1). If the patient is at a high risk of disease
exposure, if an infection could cause harm to the mother or
fetus or if the vaccine is unlikely to cause harm the benefits
of vaccinating could outweigh the potential risks. 4 Finally,
the mother's current and past medical history, including allergy to any component of the vaccine product, must be
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taken into consideration when determining whether she
should receive a specific vaccine.
Recommended Vaccines
Influenza (Inactivated)
It is recommended by the American College of Obstetricians
and Gynecologists (ACOG), the U.S. Advisory Committee on
Immunization Practices (ACIP) and the Centers for Disease
Control and Prevention (CDC) that women who are pregnant
during influenza season should receive an inactivated influenza vaccine during any trimester of pregnancy.s.6 It is recommended that pregnant women be given the inactivated
injectable influenza vaccine instead of the live attenuated
influenza vaccine (LAIV) administered as a nasal spray,
which is contraindicated during pregnancy. 7
Certain populations have a higher risk of morbidity and mortality as a result from contracting an influenza infection, one
of which are women who are pregnant.7 During pregnancy,
healthy women have a four- to fivefold increase in risk of
developing a serious illness requiring hospitalization due to
being infected with the influenza virus compared to nonpregnant, healthy females.6
There is a limited amount of research on influenza infections
in pregnant women due to the exclusion of pregnant patients
from controlled, randomized trials and toxicity testing. 7
These limited data indicate that use of the inactivated vaccine during any trimester of pregnancy is effective with no
recognized risks to the fetus. However, the possibility of fetal
hypoxia due to an anaphylactic reaction of the mother to the
vaccine's components (due to an allergy such as an egg allergy) must be considered.7
Tetanus, Diphtheria, and Pertussis (Tdap)
Pertussis is a contagious, respiratory illness, also known as
whooping cough, which is caused by the bacteria Bordetella
pertussis.B According to the CDC, there has been an increase
in the number of outbreaks of pertussis in 2012 throughout
the United States, with nearly 34,000 cases reported. Of these
cases, 16 deaths have occurred, with the majority of these
occurring in infants less than three months old.9 Tetanus is
caused by the bacteria Clostridium tetani transmitted
through contaminated, punctured, or deep tissue wounds. In
the past few years, an average of 29 cases were reported in
the United States, with about half of the patients being SO
years of age or older. Most of the cases are due to not receiving the primary vaccine series or not following up with the
booster vaccine.10 The bacteria Corynebacterium diphtheria can
be acquired through the nasopharynx or cutaneously. Diphtheria occurrence in the United States has greatly decreased in the
past few years and is rare in the United States; however, it continues to be endemic in other parts of the world.11
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Table 1. Summary of Immunization Guidelines for Pregnant Women. 4, z4
Route

Form

Vaccine

General Recommendation

Hepatitis A

Inactivated

IM

May be used if benefit outweighs risk

Hepatitis B

Inactivated

IM

Recommended in some circumstances

Herpes zoster (shingles)

Live

SC

Contraindicated

Human papillomavirus (HPV)

Inactivated

IM

"NotrecoIIlillended

Influenza, trivalent inactivated

Inactivated

IM,ID

Recommended

Influenza, live attenuated (LAIV)

Live

"Nasal
spray

Contraindicated

Measles, mumps, rubella (MMR)

Live

SC

Contraindicated

Meningococcal conjugate (MCV4)

Inactivated

IM

Inadequate data for recommendation

Tetanus, diphtheria, pertussis (Tdap)

Inactivated

IM

Recommended

Varicella

Live

SC

Contraindicated

IM= intramuscular; ID= intradermal; SC= subcutaneous

Currently, the CDC recommends that pregnant women who
have not been previously vaccinated with Tdap receive one
dose of Tdap preferably later in pregnancy (after 20 weeks
gestation) to confer the greatest protection to the newborn.
If a Td booster is indicated for a pregnant woman for wound
management, and she has not previously received a Tdap
vaccine, Tdap should be administered. Recently, the ACIP
endorsed a provisional recommendation that all pregnant
women, regardless of vaccination history, receive a Tdap
dose during the third trimester or post-partum; this recommendation has not yet been fully endorsed by the CDC. 12
If a woman does not receive this vaccine during her preg-

nancy, it is recommended to be given immediately after delivery while still in the health care facility.4 Likewise, it is
recommended that close contacts of the newborn
(immediate and extended family members and caregivers)
receive vaccine at least two weeks before interacting with
the infant. Due to the re-emergence of pertussis in the
United States, this strategy, known as "cocooning," is being
advocated to reduce transmission to newborns who are too
young to receive the vaccine themselves.13
Vaccines That May Be Used In Some Circumstances
Hepatitis A
There are two hepatitis A inactivated vaccines licensed for
use in the United States. The safety of these vaccinations during pregnancy has not been completely determined, but the
risk could be assumed to be low since it is not a live vaccine.14 Since there is no definitive evidence on the safety of
the vaccine, the risk associated with receiving the vaccination should be compared against the risk for hepatitis A in a
pregnant woman who may or may not be at a high risk for
exposure to the virus.1s
Hepatitis B
Hepatitis B virus (HBV) is prevalent worldwide and is reJanuary 2013 Volume 4, Issue 1

sponsible for one million deaths per year. There is a higher
prevalence in developing countries with limited medical facilities, and it is most common in young adults. The virus can
be transmitted perinatally from mother to infant at birth.16
The impact of perinatal transmission is indicated by the fact
that approximately 40 percent of infants born to infected
mothers in the United States develop chronic HBV. In order
to decrease the risk of transmission during birth, preventive
measures, such as screening pregnant women for the
presence of the hepatitis 8 surface antigen (HBsAg), can be
instituted.17 The presence of HBsAg in serum signifies an
infection, and the carrier rates for this antigen are 10 to 15
percent.16 Additional preventive measures include individual
case management of women and infants with HBV, immunoprophylaxis given to infants born of infected women, and a
continued series of HBV vaccines for the infant.17 Due to perinatal transmission, it is recommended that pregnant women
at high risk of contracting HBV receive the hepatitis B vaccine. Women at high risk include those being evaluated or
treated for a sexually transmitted infection (STI), those who
have had more than one sex partner in the past six months,
those using injection drugs and those who have had
intercourse with a HBsAg positive partner.4 The vaccine is a
recombinant DNA or plasma-derived vaccine, containing noninfectious HBsAg, which is given in three doses via the intramuscular route. 16 Limited data infer that fetuses of women who
receive the vaccine are at low risk for adverse effects. 4
Since the vaccine contains a noninfectious antigen for hepatitis B, the vaccine is not contraindicated for pregnant women.
If the mother is immunized, the antibodies may passively
transfer to the fetus. A study was conducted to test the efficacy of two different dosing regimens during pregnancy,
where the first group received two doses of the vaccine and
the second group received three doses. Pregnant women
who received the three-dose regimen had statistically significantly higher levels of maternal antibodies. The antibody
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levels in the infants were higher in the three-dose regimen
group at the time of birth; the levels declined in the months
following delivery. The vaccine did not cause any significant
side effects during the study and the immune response was
excellent. This study concluded that the hepatitis B vaccine is
safe in pregnancy and has high immunogenic results.rn
Vaccines That Are Contraindicated/Not Recommended
Measles, Mumps and Rubella (MMR)
Measles, Mumps and Rubella (MMR) is a live, trivalent, attenuated measles, mumps and rubella vaccine. Measles,
mumps and rubella are commonly known as childhood diseases that may have some serious and even fatal complications.19 Measles is a contagious viral infection that most often
presents with fever, cough, acute rhinitis, and an erythematous, maculopapular rash.3,19 Severe side effects often include
pneumonia and encephalitis.3 Mumps is a contagious virus
often spread via air droplets, saliva or fomites. It presents
with fever, malaise, parotiditis and myalgia.19 Mumps can
lead to further complications including meningoencephalitis
and other neurologic complications such as deafness.3 Rubella, also known as the German measles, can affect children
and adults. It often has a mild presentation, but infection during the first trimester can cause serious birth defects, such as
congenital rubella syndrome (CRS), which can be cardiac,
ophthalmologic, auditory and/or neurologic in nature.19

As the MMR vaccine is a live, attenuated vaccine, it is contraindicated during pregnancy.3.4 Women should be informed to
avoid pregnancy for at least 28 days after receiving the MMR
vaccination. However, routine pregnancy testing before administering the MMR vaccine is not recommended.4 A
woman who conceives within four weeks of administration
of the MMR vaccine should be counseled on the theoretical
risk of CRS; receipt of the vaccine should not be the basis to
terminate a pregnancy.3.4 Rubella-susceptible women who
are not vaccinated because they may be pregnant should be
counseled about the risk of CRS and educated to avoid exposure to rubella; they should be vaccinated as soon as they are
no longer pregnant. 4 Pharmacists can educate all women of
childbearing potential on the importance of MMR vaccination
before pregnancy.
Herpes zoster (zoster)
The live attenuated vaccine used to prevent shingles is contraindicated for use in pregnant women. Although most
women in the age group recommended to receive the zoster
vaccine are not likely to bear children due to decreased fertility, it can be beneficial to educate high risk patients. If a
woman capable of becoming pregnant receives the vaccine,
she should wait 28 days following administration of the zoster vaccine to conceive. If a pregnant woman has inadvertently received the live attenuated vaccine within one month
of conception, in most cases, the decision to terminate a
pregnancy should not be completely based on the administration of the zoster vaccine during pregnancy.4
Varicella
The varicella virus causes the highly contagious childhood
disease commonly known as chicken-pox. It rarely causes
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serious complications, but in some cases it can cause encephalitis and pneumonia. Typically, the risk of serious
events increases with age.3
Since the varicella vaccine contains the live, attenuated
varicella zoster virus, it is contraindicated in pregnancy.3.4
Currently, the effect of the varicella vaccine on the fetus is
unknown. Non-pregnant women receiving the vaccination
should avoid becoming pregnant for one month after the injection. Women who conceive within four weeks of receipt of
the vaccine should be counseled on theoretical risks to the
fetus; pregnancy termination based on exposure to the vaccine is not warranted. 4
If a susceptible pregnant woman is exposed to the varicella
virus, administration of the varicella zoster immune globulin
(VZIG) should be strongly considered due to a higher risk of
severe varicella and complications.4 According to the CDC
guidelines, "Administration of VZIG to these women has not
been found to prevent viremia, fetal infection, congenital
varicella syndrome or neonatal varicella. Thus, the primary
indication for VZIG in pregnant women is to prevent complications of varicella in the mother rather than to protect the
fetus." 4
Human papillomavirus (HPV)
About twenty million Americans are currently infected by
the human papillomavirus (HPV), and each year 6 million
more are infected. The vaccine may help prevent the occurrence of cervical cancer, which affects about 12,000 women
in the United States each year. There are two versions of the
vaccine available in the United States. The vaccine is given in
a three-dose series and is recommended for individuals aged
nine to 26 years. 20 The CDC states that the HPV vaccine is not
recommended for pregnant women. If a woman discovers
she is pregnant between doses of the vaccine, it is preferred
that she wait until the end of her pregnancy to receive the
next dose; however, no medical interventions are needed.4.21
A pregnancy test is not required before administration of the
HPV vaccine.4

Inadequate data
Meningococcal Conjugate (MCV4)
Meningococcal disease, caused by the pathogen Neisseria
meningitidis, is one of the leading causes of bacterial meningitis in the United States.22 N. meningitidis is a gram negative
diplococcus bacterium that commonly colonizes in the respiratory tract. It is transmitted by air droplets or contact with
respiratory tract secretions.23 Approximately 2400 to 3000
cases occur each year, and it is estimated that 10 to 14 percent
of cases are fatal, despite the timely administration of antibiotic therapy.22 Other serious sequelae include hearing loss,
neurologic disorders and the potential for the loss of a limb.23

Meningococcal conjugate is a tetravalent meningococcal vaccine containing polysaccharide serogroups A, C, Y, and W135 conjugated to diphtheria toxoid. It has been approved by
the U.S. Food and Drug Administration for active immunization of adolescents and adults 11 to 55 years of age.23 Routine vaccination is recommended for high-risk individuals
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including, but not limited to, military recruits, patients with
anatomic or functional asplenia, patients with terminal complement component deficiencies and college students living
in dormitories.3 However, currently there is no data available
on the safety of MCV4 during pregnancy. 4

18.
19.

20.

Conclusion
While general guidelines have been presented here, the risks
and benefits of administering specific vaccines during pregnancy must be determined for each patient.3 Table 1 summarizes the general recommendations presented in this article.
Pharmacists can educate patients about the vaccines recommended for use during pregnancy as well as the importance
of vaccinating other family members. Pharmacists can also
administer specific vaccines per state laws and protocols.
Finally, pharmacists can help protect the public's health by
reporting any exposures to vaccines during pregnancy, or
any known outcomes to mother or child, to the respective
vaccine manufacturers to be recorded in their pregnancy
registries. Through education, reporting and provision of
services, pharmacists can promote public health and primary
prevention.
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